BG
AKBA icon

BlackRock Group’s Akebia Therapeutics AKBA Stock Holding History

BlackRock Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-24,000
Closed -$667K – 2834
2014
Q2 		$667K Buy
+24,000
New +$578K ﹤0.01% 2056

Other funds holding AKBA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Group's AKBA Position: Q3 2014 in Review

BlackRock Group sold out of Akebia Therapeutics (AKBA) in Q3 2014, closing a stake of 24,000 shares — an estimated $667K sold.

BlackRock Group first reported a position in AKBA in Q2 2014 and held it in 1 quarter. The position peaked at $667K in Q2 2014. 51 funds tracked by Wall St. Rank hold AKBA as of Q3 2014.

  • BlackRock Group reported no remaining Akebia Therapeutics position as of Q3 2014 after selling out during the quarter.
  • BlackRock Group sold 24,000 Akebia Therapeutics shares in Q3 2014, an estimated $667K.
  • BlackRock Group first reported a position in Akebia Therapeutics in Q2 2014 and held it in 1 quarter.
  • BlackRock Group's Akebia Therapeutics position peaked at $667K in Q2 2014.
  • 51 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2014.

Based on BlackRock Group's 13F filing for Q3 2014, filed 29 Oct 2014.